lundi 29 mai 2017

Onco Actu du 29 mai 2017

1. Biologie

Study provides better understanding of how brain tumors ‘feed’ [MD Anderson]

2.10 Etiologie - Alcool

Alcohol and breast cancer – how big is the risk? [Cancer Research UK]

Just half a glass of wine a day may increase breast cancer risk [NHS Choices]

2.11 Etiologie - Alimentation

Red meat tied to higher risk of dying from many diseases [Reuters]

3.6 Prévention - Activité physique

Majority of time-pressed Brits walk less than a mile a day [Cancer Research UK]

3.8 Prévention - Alimentation

Drinking coffee may help prevent liver cancer, study suggests [The Guardian]

4. Dépistage, diagnostic et pronostic

Expanding waistline linked to an increased risk of cancer [NHS Choices]

Where body fat is carried can predict cancer risk [Cancer Research UK]

Why your waist measurement can predict cancer risk [The Guardian]

4.9 Dép., diag. & prono. - Sein

Preventing unnecessary breast cancer treatment [Cancer Research UK]

ASCO and the CAP Invite Comment on Focused Update to HER2 Testing Guideline in Breast Cancer [ASCO]

5. Traitements

Intensive Pre-Stem Cell Transplant Regimen May be Best for Younger Patients with AML, MDS [NCI]

5.12.2 Immunothérapies - CAR-T

Kite catches the inside track on the last leg of a race to the finish line with Novartis on a CAR-T first [EndPoints]

5.12.5 Immunothérapies - Pharma

U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) in Previously Treated Hepatocellular Carcinoma [BMS]

Startup Tilos to develop cancer-fighting antibody that emerged from MS research [FierceBiotech]

Pierre Fabre buys up Igenica preclinical I-O meds [FierceBiotech]

5.12.6 Immunothérapies - AMM

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type [Xconomy]

Immunotherapy drug opens a new era of precision medicine for cancer [LA Times]

FDA Approves First Use for an Anticancer Therapeutic Based on Tumor Biomarker, Not Tumor Origin [Cancer Research Catalyst]

An Approval Like No Other [in the Pipeline]

In Bold Move, FDA Approves Cancer Drug For Any Advanced Tumor With Genetic Changes [Forbes]

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Unresectable or Metastatic, Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient Cancer [Merck]

FDA clears Merck's Keytruda based on cancer genetics, not location [Reuters]

FDA grants accelerated approval to pembrolizumab for first tissue/site agnostic indication [FDA]

Pioneering Merck makes another breakthrough with PD-1 star Keytruda, grabbing first OK for a cancer biomarker [EndPoints]

Tissue-independent cancer drug gets fast-track approval from US regulator [Nature]

Drug Is First to Treat Cancer Based on Genetics, Not Location [MIT Technology Review]

5.3 Traitements - FDA, EMA, NICE...

Novartis receives FDA approval for expanded use of Zykadia® in first-line ALK-positive metastatic non-small cell lung cancer (NSCLC) [Novartis]

5.3.4 Traitements - AMM (FDA, EMA)

ODAC votes 12-4 to recommend approval for kinase inhibitor used after completion of trastuzumab [The Cancer Letter]

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential [The Street]

FDA Panel Votes 12 To 4 to Approve Puma's Breast Cancer Drug [Forbes]

Puma wins a big round in fight for neratinib OK as experts offer a crucial thumbs up [EndPoints]

Puma Biotechnology Receives FDA Advisory Committee Support for Neratinib [Puma]

U.S. FDA panel backs Puma Biotech's breast cancer drug [Reuters]

5.4 Traitements - Economie

Accelerated FDA approval and pricey drugs make a rotten combo, doctors argue [FiercePharma]

New FDA commissioner Gottlieb unveils price-fighting strategies [FiercePharma]

Measuring Value Based On What Matters To Patients: A New Value Assessment Framework [Health Affairs Blog]

5.5 ASCO

ASCO Launches CENTRA, a New Hub for Cancer Care Research, Data, and Analysis [ASCO]

6. Lutte contre les cancers

Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop (2017) [NAP]

6.10 Politiques

World Health Organization gets first leader from Africa [Nature]

W.H.O. Elects Ethiopia’s Tedros as First Director General From Africa [NY Times]

Ethiopia's Tedros wins WHO race, first African to get top job [Reuters]

6.10.1 Politiques (USA)

President’s Budget Threatens to Stall Nation’s Progress Against Cancer [ASCO]

Trump would cut over 20 percent of NIH, NCI budgets in new FY18 proposal [The Cancer Letter]

ASH President Responds to President Trump’s Proposal to Cut One in Five Dollars to NIH, Public Health Programs [ASH]

What’s in Trump’s 2018 budget request for science? [Science]

Trump budget would slash science programmes across government [Nature]

Cancer research, public health and worker safety would all see steep cuts under Trump budget [LA Times]

6.5 Médecines alternatives

The Natural Cancer Cure Narrative [Science-Based Medicine]

6.6 Publications

Reproducible Research, Just Not Reproducible By You [The Scholarly Kitchen]

6.7 DMP, Big Data & applis

Big Data in Biomedicine panel examines data sharing difficulties [Stanford Medicine]

6.8 Communication

Today’s alcohol and breast cancer headlines are wrong: Here’s how news reports could have done better [HealthNewsReview]

6.9 Controverses

Amy Reed, physician and patient who “moved mountains” to end widespread use of power morcellation, dies at 44 [The Cancer Letter]